The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy

Lastrucci V. et al.

Iris Unipi Prod · Other

cost–benefit analysi, hospitalization, immunization, nirsevimab, prevention, respiratory syncytial virus (rsv)

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 260116
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.